Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Erdosteine is a new thioderivative endowed with mucokinetic, mucolytic, and free-radical-scavenging properties. This study evaluated (in a double-blind design vs. placebo) its efficacy on biochemical and rheologic properties of sputum and on some indices of respiratory function in chronic patients with chronic bronchitis (10 per group), while receiving basic treatment with a controlled-release theophylline preparation. The pharmacokinetics of erdosteine and theophylline were also studied. We found that a 2 week treatment with erdosteine (300 mg 3 times daily) was able to reduce significantly (p less than 0.05) the sputum apparent viscosity, fucose content, and macromolecular dry weight (MDW) with no statistically significant influence on sputum elasticity, DNA, albumin, total proteins, total IgA, lactoferrin, and lysozyme content. The treatment caused a significant increase in the following ratios: total IgA/albumin, lactoferrin/albumin, and lysozyme/albumin. The pharmacokinetics of erdosteine, its metabolites, and theophylline were the same after 1 or 14 days of treatment, evidence both of absence of an enzymatic induction and of an accumulation process. Further confirmation that there was no interference between erdosteine and theophylline was obtained from the data available on the group of patients receiving only theophylline, since its plasma levels and related pharmacokinetic parameters were identical to those obtained in patients receiving both drugs. In conclusion, 2 weeks of therapy with erdosteine reduced the marker of mucus glycoproteins (fucose) in patients with chronic bronchitis but did not interfere with the pharmacokinetics of xanthine derivatives. We also suggest that the significant increment in the IgA/albumin ratio might be related to a sum of other local effects such as reduction of the inflammatory process and enhancement of the humoral defense mechanism.
Marchioni
C F
CF
Istituto di Tisiologia, University of Modena, Italy.
Moretti
M
M
Muratori
M
M
Casadei
M C
MC
Guerzoni
P
P
Scuri
R
R
Fregnan
G B
GB
D001991:Bronchitis / Q000188:drug therapy* / Q000378:metabolism; D002908:Chronic Disease; D004311:Double-Blind Method; D005100:Expectorants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012212:Rheology; D013183:Sputum / Q000737:chemistry*; D013806:Theophylline / Q000493:pharmacokinetics / Q000627:therapeutic use; D013864:Thioglycolates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013876:Thiophenes / Q000493:pharmacokinetics / Q000627:therapeutic use*
D005100:Expectorants; D013864:Thioglycolates; D013876:Thiophenes; C048498:erdosteine; D013806:Theophylline